Psoriasis: Clinical Trials

33 trials for Psoriasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

33 terminated. 33 Phase 2, 4 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 233Terminated 33
Phase 14Terminated 4
Phase 32Terminated 2

Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis

Trials (filtered) newest first · largest first

All 33 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis
TQH2929 Injections, TQH2929 Placebo - Generalized Pustular Psoriasis
Phase 2TerminatedChia Tai Tianqing Pharmaceutical Group Co., Ltd.362026-03-192026-08-03
TYK2 Inhibition in Paradoxical Psoriasis
Deucravacitinib - Psoriasis
Phase 2 / Phase 3TerminatedProf Curdin Conrad22024-06-202025-04-02
VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)
Dose A VTX958, Dose B VTX958, Placebo - Psoriatic Arthritis
Phase 2TerminatedVentyx Biosciences, Inc2052023-01-312024-12-27
Psoriatic Arthritis Study of Izokibep
Izokibep, Placebo to izokibep - Psoriatic Arthritis
Phase 2 / Phase 3TerminatedACELYRIN Inc.3512022-11-212025-05-23
VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis
VTX958 Dose A, VTX958 Dose B, VTX958 Dose C - Psoriasis
Phase 2TerminatedVentyx Biosciences, Inc2222022-11-172024-09-19
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
ATI-450, Placebo Oral Tablet - Psoriatic Arthritis
Phase 2TerminatedAclaris Therapeutics, Inc.472022-07-122024-11-27
Impact of Cannabis on Pain and Inflammation Among Patients With Rheumatoid or Psoriatic Arthritis
Cannabis: placebo and medium THC/medium CBD - Rheumatoid Arthritis, Psoriatic Arthritis
Phase 2TerminatedBrown University32022-05-182025-04-01
A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
RIST4721, Placebo - Palmoplantar Pustulosis
Phase 2TerminatedAristea Therapeutics, Inc.792022-01-052023-06-29
A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis
Cedirogant, Placebo - Psoriasis
Phase 2TerminatedAbbVie1562021-11-162023-11-29
A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab
Spesolimab - Palmoplantar Pustulosis
Phase 2TerminatedBoehringer Ingelheim1082020-09-042025-10-20
A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is
BI 730357, Placebo to match BI 730357 - Psoriasis
Phase 2TerminatedBoehringer Ingelheim1652019-03-182022-11-18
Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
Icotinib hydrochloride cream, Placebo cream - Mild to Moderate Psoriasis
Phase 2TerminatedBetta Pharmaceuticals Co., Ltd.1362017-11-292018-11-14
Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis
JTE-051, Placebo - Plaque Psoriasis, Skin Diseases
Phase 2TerminatedAkros Pharma Inc.132017-11-102021-08-06
A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis
BMS-986251, Placebo - Rheumatoid Arthritis, Psoriasis
Phase 1 / Phase 2TerminatedBristol-Myers Squibb382017-11-022019-10-21
99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis
rhAnnexin V-128 - Spondyloarthritis
Phase 2TerminatedAdvanced Accelerator Applications52017-09-182019-12-13
An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.
filgotinib - Psoriatic Arthritis
Phase 2TerminatedLakefront Biotherapeutics NV1222017-07-262022-04-21
Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06
DFD06 - Psoriasis
Phase 2TerminatedPrimus Pharmaceuticals222017-05-022024-03-07
A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197
ABT-122 - Psoriatic Arthritis
Phase 2TerminatedAbbVie1682015-10-012016-06-17
Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis
PF-04965842, Placebo - Plaque Psoriasis
Phase 2TerminatedPfizer592014-11-012016-10-05
AMG 827 in Subjects With Psoriatic Arthritis
AMG 827 140, Placebo, AMG 827 280 - Psoriatic Arthritis
Phase 2TerminatedBausch Health Americas, Inc.1682011-10-012020-08-27

Showing 20 of 33. Sign in to see all of them.

Narrower conditions

Arthritis, Psoriatic (11)  ·  Arthritis (3)  ·  Arthritis, Rheumatoid (2)  ·  Dermatitis, Atopic (2)  ·  Inflammatory Bowel Diseases (2)  ·  Skin Diseases (2)  ·  Spondylitis, Ankylosing (2)  ·  Alopecia (1)  ·  Eczema (1)  ·  Lymphoma, Follicular (1)  ·  Lymphoma, T-Cell, Cutaneous (1)  ·  Musculoskeletal Diseases (1)  ·  Mycosis Fungoides (1)  ·  Non-alcoholic Fatty Liver Disease (1)

Broader conditions

Skin Diseases, Papulosquamous (33)  ·  Skin and Connective Tissue Diseases (33)  ·  Skin Diseases (31)  ·  Bone Diseases (12)  ·  Joint Diseases (12)  ·  Spinal Diseases (12)  ·  Spondylitis (12)  ·  Musculoskeletal Diseases (11)  ·  Spondylarthritis (11)  ·  Spondylarthropathies (11)  ·  Arthritis (9)  ·  Immune System Diseases (5)  ·  Ankylosis (2)  ·  Autoimmune Diseases (2)

Interventions

teplizumab (2)  ·  5-(9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro(4,4)non-7-ylmethyl)-3-thiophenecarboxylic acid (1)  ·  ABT-122 (1)  ·  Abatacept (1)  ·  Adalimumab (1)  ·  Clobetasol (1)  ·  Folic Acid (1)  ·  GLPG0634 (1)  ·  Penicillin G Benzathine (1)  ·  Pyridoxine (1)  ·  Vitamin B 12 (1)  ·  Vitamin B 6 (1)  ·  abrocitinib (1)  ·  brodalumab (1)  ·  deucravacitinib (1)

Sponsors

Bristol-Myers Squibb (3)  ·  AbbVie (2)  ·  Bausch Health Americas, Inc. (2)  ·  Boehringer Ingelheim (2)  ·  Ventyx Biosciences, Inc (2)  ·  ACELYRIN Inc. (1)  ·  Aclaris Therapeutics, Inc. (1)  ·  Advanced Accelerator Applications (1)  ·  Akros Pharma Inc. (1)  ·  Aristea Therapeutics, Inc. (1)  ·  Betta Pharmaceuticals Co., Ltd. (1)  ·  Brown University (1)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)  ·  Eli Lilly and Company (1)  ·  Lakefront Biotherapeutics NV (1)

Countries

United States (23)  ·  Canada (12)  ·  Poland (8)  ·  Germany (7)  ·  Czechia (6)  ·  Hungary (5)  ·  Spain (5)  ·  Australia (4)  ·  Bulgaria (4)  ·  Belgium (3)  ·  France (3)  ·  China (2)  ·  Italy (2)  ·  Japan (2)  ·  Netherlands (2)

Top investigators

Alice B Gottlieb, MD, PhD (1)  ·  Curdin Conrad, Professor (1)  ·  Elias Rosenberg, MD (1)  ·  Elizabeth Aston, PhD (1)  ·  Heikki T Mansikka, MD (1)  ·  John J Voorhees, MD (1)  ·  Luigi Naldi, dermatology (1)  ·  Marcus Clark, MD (1)  ·  Matt Cascino, MD (1)  ·  Melissa Magliocco, MD (1)  ·  Min Zheng, PHD (1)

Results publications

PMID 18645136, PMID 21128258, PMID 24434748, PMID 26773108, PMID 30032191, PMID 31493163, PMID 32207067, PMID 35061234, PMID 35137002, PMID 35342978, PMID 36919398, PMID 38896380, PMID 39848568

NIH funding

2017 (2), 2014 (1), 2018 (1), P20GM130414 (1)